Earliest Stage Treatment of Aktinic Keratosis With Imiquimod 3.75% Cream

Medical University of Graz48 enrolled

Overview

Earliest Stage Treatment of Actinic Keratosis with Imiquimod 3.75% Cream: The study is to demonstrate that Aktinic Keratosis are present before they are clinically visible, i.e. in a subclinical stage. Since on the basis of the research situation, also subclinical AK can proliferate into the dermis, it is possible that with the application of Imiquimod on chronically light-exposed skin, undetected squamous cell carcinoma can be recognized and treated at the same time.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Actinic Keratoses

Interventions

Imiquimod 3.75% CreamDRUG

Imiquimod 3.75% Cream

Eligibility

Sex: FEMALEMin age: 50 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion * Male and female supposed-healthy volunteer outpatients, age: \> 50 years. * Diagnosis: patients with chronically UV-exposed photodamaged facial skin. * Consent by signing the ICF (Informed Consent Form) Exclusion * Current participation in another clinical trial * Patients who are using topical glucocorticoids on the face. * Known intolerance/hypersensitivity to imiquimod * Pregnant/breastfeeding women * Systemic disease, immunodeficiency

Locations (1)

Universitätsklinik für Dermatologie und Venerologie

Graz, Austria

Outcomes

Primary Outcomes

immunomodulatory-induced inflammatory reaction

Percentage of subjects in whom an immunomodulatory-induced inflammatory reaction occurs on chronically light-exposed uv-damaged facial skin after two weeks.

Time frame: two weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.